JMP Securities started coverage on shares of Aclaris Therapeutics Inc. (NASDAQ:ACRS) in a research report sent to investors on Friday morning. The firm issued an outperform rating and a $34.00 target price on the stock.
Other analysts have also issued reports about the company. Jefferies Group raised their price target on Aclaris Therapeutics from $23.00 to $31.00 and gave the stock a buy rating in a research note on Monday, September 19th. Guggenheim started coverage on Aclaris Therapeutics in a research note on Friday, June 10th. They issued a buy rating and a $35.00 price target on the stock. Finally, Zacks Investment Research raised Aclaris Therapeutics from a sell rating to a hold rating in a research note on Tuesday, September 6th. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the company. The stock currently has a consensus rating of Buy and an average price target of $31.80.
Aclaris Therapeutics (NASDAQ:ACRS) traded up 0.43% during mid-day trading on Friday, hitting $25.72. 12,506 shares of the company were exchanged. The stock’s market cap is $550.79 million. The firm has a 50 day moving average price of $22.46 and a 200 day moving average price of $20.11. Aclaris Therapeutics has a 12 month low of $10.99 and a 12 month high of $33.88.
Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings data on Thursday, August 11th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.61) by $0.01. Analysts anticipate that Aclaris Therapeutics will post ($2.60) EPS for the current fiscal year.
In other news, insider Kamil Ali-Jackson sold 1,841 shares of Aclaris Therapeutics stock in a transaction dated Wednesday, September 28th. The stock was sold at an average price of $24.66, for a total value of $45,399.06. Following the transaction, the insider now directly owns 77,798 shares of the company’s stock, valued at approximately $1,918,498.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Ra Capital Management, Llc sold 525,550 shares of Aclaris Therapeutics stock in a transaction dated Friday, September 16th. The shares were sold at an average price of $24.19, for a total value of $12,713,054.50. The disclosure for this sale can be found here. 46.40% of the stock is owned by insiders.
Several institutional investors have recently added to or reduced their stakes in the stock. Nationwide Fund Advisors raised its position in Aclaris Therapeutics by 47.0% in the second quarter. Nationwide Fund Advisors now owns 5,747 shares of the company’s stock valued at $106,000 after buying an additional 1,838 shares in the last quarter. BlackRock Institutional Trust Company N.A. increased its stake in shares of Aclaris Therapeutics by 24.3% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 28,286 shares of the company’s stock valued at $536,000 after buying an additional 5,535 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Aclaris Therapeutics by 18.3% in the first quarter. Geode Capital Management LLC now owns 43,246 shares of the company’s stock valued at $819,000 after buying an additional 6,679 shares during the last quarter. California State Teachers Retirement System increased its stake in shares of Aclaris Therapeutics by 54.7% in the second quarter. California State Teachers Retirement System now owns 18,896 shares of the company’s stock valued at $349,000 after buying an additional 6,683 shares during the last quarter. Finally, Geduld E E increased its stake in shares of Aclaris Therapeutics by 62.5% in the second quarter. Geduld E E now owns 17,500 shares of the company’s stock valued at $323,000 after buying an additional 6,729 shares during the last quarter. 71.39% of the stock is currently owned by institutional investors and hedge funds.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies in dermatology. The Company’s drug candidate, A-101 is being developed as an in-office treatment for seborrheic keratosis, a non-cancerous skin tumor, as well as for other cutaneous indications, such as common warts.
Receive News & Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.